Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving sorafenib with interferon alfa works in
treating patients with metastatic or unresectable kidney cancer. Sorafenib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa
may interfere with the growth of tumor cells and slow the growth of kidney cancer. Sorafenib
may help interferon alfa work better by making tumor cells more sensitive to the drug